FluoGuide prioritizes a direct dialogue with our shareholders and investors. Besides public presentations, FluoGuide also has meetings with individuals or groups of investors regularly.

New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

New exchange: Nasdaq First North


Latest presentation can be downloaded here.

Presentation at Redeye Life Science Day 2022

24 November 2022

Presentation on interim results from phase lla in lung cancer (in Danish)

15 November 2022

Presentation at Redeye Medtech Seminar 2022

26 October 2022

Presentation at Redeye Investor AW in Malmö

16 September 2022

Presentation at the ABGSC Investor Day

13 September 2022

Investor presentation on updated clinical development strategy

25 August 2022

Presentation at the ABGSC Life Science Summit

19 May 2022

Presentation of FG001 results from the first clinical trial in aggressive brain cancer

17 May 2022

Kapital Partner Life Science Seminar

18 May 2022

FluoGuide presenting at Kapital Partner Life Science seminar

Redeye Orphan Drugs Seminar

27 April 2022

Sedermera dagen in Stockholm

25 April 2022

Presentation of directed issue outcome

14 March 2022

Life Science Investor Conference

23 February 2022

Presentation Redeye Initiate 2021

8 December 2021

Presentation ABG Investor day

7 December 2021

Presentation at Redeye Life Science Day

11 November 2021

Life Science konference Økonomiske ugebrev

20 October 2021

FG001 safety data presentation

11 October, 2021

Redeye Investor Forum in Göteborg

16 September, 2021

Pareto Securities 12th Annual Healthcare Conference

2 September 2021